The industry’s top-selling drugs generate billions in revenues each year. Scrip analyzed data on nearly 200 blockbuster drugs to see which are forecast to make the most at peak and over a 14-year time horizon.

Public Company Edition: Verona Pharma arranged up to $400m in new debt and up to $250m in revenue-related financing ahead of its COPD drug launch. Also, Organon, Sobi and Pacira priced $1bn, $275.1m and $250m note sales, respectively. Marinus, Emergent and Ginkgo cut jobs.

Months after an antitrust lawsuit challenged its deal with Sanofi and raised uncertainty about the future of MZE001, Maze secured a new partner for potentially the first oral Pompe disease drug.

A more than 70% stock slide shows that investors are concerned about three as-yet unexplained deaths in a Phase II study of the US firm’s lead candidate.